MPM Asset Management Investors BV2014 LLC insider trades
MPM Asset Management Investors BV2014 LLC has filed 5 Form 4s with the SEC that we hold, for Werewolf Therapeutics, Inc. (HOWL) (10% owner), Entrada Therapeutics, Inc. (TRDA) (10% owner) and ITOS (10% owner). Across all of them we count 1 purchase worth $2.0M and 9 sales worth $1.5M reported on Form 4. In the last 12 months: 0 purchases ($0) and 6 sales ($528.5K). The largest single trade was a purchase of 100,000 shares of Entrada Therapeutics, Inc. worth $2.0M, dated 2021-11-02. The first filing on our record is dated 2021-09-23 and the latest 2025-12-01.
Werewolf Therapeutics, Inc. (HOWL)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-03-27 | S, sale reported on Form 4 | 1,963 | $2.1K | 2025-04-30 |
| 2025-10-30 | S, sale reported on Form 4 | 86,936 | $124.3K | 2025-11-03 |
| 2025-10-31 | S, sale reported on Form 4 | 114,044 | $146.0K | 2025-11-03 |
| 2025-11-03 | S, sale reported on Form 4 | 94,063 | $121.3K | 2025-11-03 |
| 2025-11-26 | S, sale reported on Form 4 | 60,733 | $59.5K | 2025-12-01 |
| 2025-11-28 | S, sale reported on Form 4 | 20,277 | $20.1K | 2025-12-01 |
| 2025-12-01 | S, sale reported on Form 4 | 60,917 | $57.3K | 2025-12-01 |
Entrada Therapeutics, Inc. (TRDA)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-11-02 | P, purchase reported on Form 4 | 100,000 | $2.0M | 2021-11-04 |
ITOS
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-21 | S, sale reported on Form 4 | 19,635 | $539.4K | 2021-09-23 |
| 2021-09-22 | S, sale reported on Form 4 | 14,294 | $393.7K | 2021-09-23 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1609495) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms